In preclinical models, inhibition of Tim-3 by anti-Tim-3 monoclonal antibodies, either as monotherapy or in combination with anti-PD-1 or anti-CTLA-4, has shown improved anti-tumor effects and growth inhibition [119,121]. The gene discussed is CTLA4; the disease is neoplasm.